The Cooper Companies, Inc.

The stock is in a recovery phase after a long pullback, trading back above its 50-day average but still below the 200-day trend line. It remains well under the 52-week high of 89.83, so the setup is improving but not fully repaired.

Street sentiment leans constructive, with a Buy consensus and an average target around 80.33 versus the last close near 71. Recent calls have been mixed but mostly target trims, including 86 at Needham, 66 at Wells Fargo, and 85 at Mizuho, which points to cautious optimism rather than broad enthusiasm.

The next report follows a solid beat in June, when EPS came in at 1.21 versus 1.10 expected. Longer term, the pattern is uneven, but next-year EPS estimates still point to 4.9966, so shareholders should watch whether margin recovery and demand can support that step-up.

No discretionary insider buying or selling stands out. The recent filings are dominated by award and exempt/vesting-related transactions, which read as routine compensation activity rather than a directional signal.

Profitability is mixed but not broken: gross margin is 65.5% and net margin is 5.57%, while operating margin is still negative at -2.87%. Growth is healthy, with revenue up 7.9% year over year and earnings up 26.9%, and free cash flow of $1.16 billion provides useful support.

COO sits in a defensible healthcare niche with contact lenses and women’s health products, which supports steadier demand than many medtech peers. Valuation is not stretched at 15.57 times earnings, leaving room if execution improves, though the balance sheet remains leveraged.